Erratum: Fedratinib in myelofibrosis (Blood Advances (2020) 4:8 (1792-1800) DOI: 10.1182/bloodadvances.2019000954)

A. Mullally, J. Hood, C. Harrison, R. Mesa

Research output: Contribution to journalComment/debatepeer-review


In the next-to-last line on page 1792, “frontline” should be deleted. In the third line under “Fedratinib approval and clinical utilization implications” on page 1796, “(NCT03755518, frontline; NCT03952039, second line)” should read, “(NCT03755518 and the second-line NCT03952039).” In the second and third lines of the right column of page 1798, “a frontline trial for additional safety data” should read “an efficacy and safety trial of fedratinib in myelofibrosis previously treated with ruxolitinib.” The errors have been corrected in the published article.

Original languageEnglish (US)
Pages (from-to)3315
Number of pages1
JournalBlood Advances
Issue number2
StatePublished - Jul 28 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Erratum: Fedratinib in myelofibrosis (Blood Advances (2020) 4:8 (1792-1800) DOI: 10.1182/bloodadvances.2019000954)'. Together they form a unique fingerprint.

Cite this